|Mr. Hervé Hoppenot||Chairman, Pres & CEO||2.02M||N/A||1960|
|Ms. Maria E. Pasquale||Exec. VP & Gen. Counsel||959.71k||N/A||1966|
|Dr. Wenqing Yao||Exec. VP & Head of Discovery Chemistry||687.16k||N/A||1963|
|Dr. Steven H. Stein||Exec. VP & Chief Medical Officer||758.62k||N/A||1967|
|Ms. Christiana Stamoulis||Exec. VP & CFO||N/A||N/A||1971|
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Incyte Corporation’s ISS Governance QualityScore as of December 3, 2019 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 7; Compensation: 10.